Develops an investigational cell therapy for bladder cancer and lymphatic malformations, plus an intravenous choline treatment for patients receiving nutrition and fluids through a vein.
10-K for FY2025, filed Mar 10, 2026
10-Q for Q3 FY2026, filed Nov 6, 2026
−$21.7MView ↗
Broader choline-treatment use
The earlier report described choline treatment for people receiving parenteral nutrition who had intestinal failure-associated liver disease. The latest report describes it as a choline source when nutrition by mouth or through the digestive tract cannot be used, is inadequate, or is contraindicated.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 10, 2026The third development program in our portfolio is intravenous, or IV, Choline Chloride, an investigational phospholipid substrate…View ↗
In April 2024, we announced alignment with the FDA on a registrational path forward for IV Choline Chloride. Previously, we had been…View ↗
Competes with Merck &, Endo International, Ferring, ImmunityBio, Janssen, Japanese BCG Laboratory, Pfizer, CG Oncology, enGene, Urogen Pharma, Theralase Technologies, Auro BioSciences, Verity, AstraZeneca, Bristol-Myers Squibb, Roche Group, Asieris Pharmaceuticals, BeiGene, NanOlogy, and Linton Pharm
10-K for FY2025, filed Mar 10, 2026TARA-002, if approved for the treatment of NMIBC, would be subject to competition from existing treatment methods of surgery, chemotherapy…View ↗
Loading...